Streptococcal preparation OK-432 is a bacterial immunopotentiator extensively used in Japan for adjuvant cancer therapy. Using C3H/He mice bearing MH-134 tumour cells, cytokine inductions of tumour necrosis factor-α, interleukin 1β interleukin 6 and interferon-γ were determined in spleen and tumour tissues by reverse transcriptase-polymerase chain reaction analysis. No significant induction of cytokine mRNA was observed after subcutaneous administration of OK-432 (OK-432, sc) or after intratumoural injection of IFN-γ (IFN-γ, it), compared with controls, either in spleen or tumour tissues. In contrast, subcutaneous administration of OK-432 followed by intratumoural OK-432 injection (OK-432, sc+it) was found to induce some cytokine mRNAs significantly. The mRNA levels of tumour necrosis factor α and interferon-γ in spleen tissue and those of interleukin 1β and interferon-γ in tumour tissues were significantly elevated in mice with OK-432, sc+it treatment compared with controls. These results suggest that treatment with OK-432, sc+it effectively induced splenic antitumour immunity as well as local immunity against tumour cells.
TalmadgeJEHerbermanRBThe preclinical screening laboratory: evaluation of immunomodulatory and therapeutic properties of biological response modifiers. Cancer Treat Res1986; 70: 171–182.
2.
WatanabeYIwaTClinical value of immunotherapy for lung cancer by the streptococcal preparation OK-432. Cancer1987; 6: 169–180.
3.
MukaiMKubotaSMoritSA pilot study of combination therapy of radiation and local administration of OK-432 for esophageal cancer. Cancer1995; 75: 2276–2280.
4.
TanakaNGouchiAOharaTIntratumoral injection of a streptococcal preparation, OK-432, before surgery for gastric cancer. Cancer1994; 74: 3097–3103.
5.
MaeharaYOkuyamaTKakejiYPostoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion. Am J Surg1994; 168: 36–40.
6.
FukuiHKoishiharaYNagamutaMProduction of interleukin 6 by human spleen cells stimulated with streptococcal preparation OK-432. Immunol Lett1989; 21: 127–130.
7.
IchimuraOSuzukiSSaitoMAugmentation of interleukin 1 and interleukin 2 production by OK-432. Int J Immunopharmacol1985; 7: 263–270.
8.
OshimiK.KanoSTakakuFAugmentation of mouse natural killer cell activity by a streptococcal preparation, OK-432. J Natl Cancer Inst1980; 65: 1265–1269.
9.
SaitoMEbinaTKoiMInduction of interferon gamma in mouse spleen cells by OK-432, a preparation ofStreptococcus pyogenes. Cell Immunol1982; 68: 187–192.
10.
MisakiTWatanabeYIidaYRecruitment of T lymphocytes and induction of tumor necrosis factor in thyroid cancer by a local immunotherapy. Cancer Immunol hnmunother1992; 35: 92–96.
11.
YamaueHTanimuraHIwahashiMRole of interleukin-2 and interferon-γ in induction of activated natural killer cells from mice primed in vivo and subsequently challenged in vitro with the streptococcal preparation OK-432. Cancer Immunol Immunother1989; 29: 79–86.
12.
ChomczynskiPSacchiNA new method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem1987; 162: 156–159.
13.
TanabeOAkiraSKaniyaTGenomic structure of the murine IL-6 gene: high degree conservation of potential regulatory sequences between mouse and human. J Immunol1988; 141: 3875–3881.
14.
TorisuMKatanoMKimuraYNew approach to management of malignant ascites with a streptococcal preparation, OK-432. Improvement of host immunity and prolongation of survival. Surgery1983; 93: 357–364.
15.
KatanoMYamamotoHKubotaEThe possible use of spleen cells for the adoptive immunotherapy of cancer patients. Surg Today1993; 23: 13–20.
16.
YamagishiHUedaYOkaTA case report of immunotherapy on a patient with advanced gastric cancer by adoptive transfer of OK-432-reactive HLA-matched allogeneic lymphocytes. Cancer Immunol Immunother1998; 46: 113–119.
17.
KirkwoodJMWilsonJWhitesideTLPhase 1B trial of picibanil (OK-432) as an immunomodulator in patients with resected high-risk melanoma. Cancer Immunol Immunother1997; 44: 137–149.
18.
D'AndreaARengarajuMValianteNMProduction of natural killer cell stimulator factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med1992; 176: 1387–1398.
19.
WysockaMKubinMVieiraLQInterleukin-12 is required for interferon-γ production and lethality in lipopolysaccharide-induced shock in mice. Eur J Immunol1995; 25: 672–676.
20.
TrinchieriGInterleukin-12: a cytokine produced by antigen-presenting cell with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood1994; 84: 4008–4027.
21.
GatelyMKWarrierRRHonasogeSAdministration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production on LFN-γ in vivo. Int Immunol1994; 6: 157–167.
22.
BohnEAutenriethIBIL-12 is essential for resistance against Yersinia enterocolitica by triggering IFN-γ production in NK cells and CD4+ T cells. J Immunol1996; 156: 1458–1468.
23.
ChanSHPerussiaBGuptaJWInduction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med1991; 173: 869–879.
24.
HeinzelFPRerkoPMLingPInterleukin-12 is produced in vivo during endotoxemia and stimulates synthesis of gamma-interferon. Infect Immun1994; 62: 4244–4249.
25.
MagramJConnaughtonSEWarrierRRIL-12 deficient mice are defective in IFN gamma production and type 1 cytokine responses. Immunity1996; 4: 471–481.
26.
BrundaMJLuistroLWarrierRRAntitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med1993; 178: 1223–1230.
27.
TannenbaumCSWickerNArmstrongDCytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J Immunol1996; 156: 693–699.
28.
FujimotoTDudaRBSzilvasiAStreptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state, J Immunol1997; 158: 5619–5626.
29.
FleschIEAHessJHHuangSEarly interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon-γ and tumor necrosis factor-α. J Exp Med1995; 181: 1615–1621.
30.
MaXD'AndreaAKubinMProduction of interleukin-12. Res Immunol1995; 146: 432–438.
31.
TrippCSWolfSFUnanueERInterleukin 12 and tumor necrosis factor a are costimulators of interferon γ production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc Natl Acad Sci USA1993; 90: 3725.
32.
YamamotoNZouJPLiXFRegulatory mechanisms for production of IFN-γ and TNF by antitumor T cells or macrophages in the tumor-bearing state. J Immunol1995; 154: 2281–2290.
33.
BarthRJJrMuleJJSpiessPJRosenbergSAInterferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med1991; 173: 647–658.
34.
BrundaMJSulichVBellantoniDThe anti-tumor effect of recombinant interferon alpha and gamma is influenced by tumor location. Int J Cancer1987; 40: 807–810.
35.
MacIejewskiJSelleriCAndersonSFas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood1995; 85: 3183–3190.
